R Valenta

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi Hom s 4, an IgE-reactive autoantigen belonging to a new subfamily of calcium-binding proteins, can induce Th cell type 1-mediated autoreactivity
    Karl J Aichberger
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Immunol 175:1286-94. 2005
  2. ncbi Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches
    R Valenta
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria
    J Intern Med 272:144-57. 2012
  3. ncbi Vaccines for allergy
    Birgit Linhart
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Austria
    Curr Opin Immunol 24:354-60. 2012
  4. ncbi Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections
    Katarzyna Niespodziana
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    FASEB J 26:1001-8. 2012
  5. ncbi Tracing antigen signatures in the human IgE repertoire
    Katharina Marth
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Mol Immunol 47:2323-9. 2010
  6. ncbi Recombinant allergens: what does the future hold?
    Rudolf Valenta
    Christian Doppler Laboratory for Allergy Research, Medical University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 127:860-4. 2011
  7. ncbi Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation
    J Edlmayr
    Division of Immunopathology, Dept of Pathophysiology, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Eur Respir J 37:44-52. 2011
  8. ncbi Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens
    Rudolf Valenta
    Christian Doppler Laboratory for Allergy Research, Vienna, Austria
    Allergy 66:775-83. 2011
  9. ncbi From allergen genes to allergy vaccines
    Rudolf Valenta
    Medical University of Vienna, Austria
    Annu Rev Immunol 28:211-41. 2010
  10. ncbi Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination
    M Focke
    Department of Pathophysiology, Vienna General Hospital, Medical University of Vienna, Austria
    Clin Exp Allergy 34:1525-33. 2004

Detail Information

Publications145 found, 100 shown here

  1. ncbi Hom s 4, an IgE-reactive autoantigen belonging to a new subfamily of calcium-binding proteins, can induce Th cell type 1-mediated autoreactivity
    Karl J Aichberger
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Immunol 175:1286-94. 2005
    ..It may thus contribute to chronic skin inflammation in atopic as well as in nonatopic persons...
  2. ncbi Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches
    R Valenta
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria
    J Intern Med 272:144-57. 2012
    ..Finally, we discuss possible allergen-specific strategies for prevention of allergic disease...
  3. ncbi Vaccines for allergy
    Birgit Linhart
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Austria
    Curr Opin Immunol 24:354-60. 2012
    ..Successful clinical trials performed with the new vaccines indicate that broad allergy vaccination is on the horizon and may help to control the allergy pandemic...
  4. ncbi Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections
    Katarzyna Niespodziana
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    FASEB J 26:1001-8. 2012
    ..Based on these findings, it may be possible to design vaccines against RV infections and RV-induced respiratory diseases...
  5. ncbi Tracing antigen signatures in the human IgE repertoire
    Katharina Marth
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Mol Immunol 47:2323-9. 2010
    ..Our results indicate that allergens select and shape a limited number of similar IgE variable regions in the human IgE repertoire...
  6. ncbi Recombinant allergens: what does the future hold?
    Rudolf Valenta
    Christian Doppler Laboratory for Allergy Research, Medical University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 127:860-4. 2011
    ....
  7. ncbi Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation
    J Edlmayr
    Division of Immunopathology, Dept of Pathophysiology, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Eur Respir J 37:44-52. 2011
    ..They exhibited strong cross-neutralising activity for different HRV strains. Therefore, recombinant VP1 may be considered a candidate HRV vaccine to prevent HRV-induced asthma exacerbations...
  8. ncbi Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens
    Rudolf Valenta
    Christian Doppler Laboratory for Allergy Research, Vienna, Austria
    Allergy 66:775-83. 2011
    ....
  9. ncbi From allergen genes to allergy vaccines
    Rudolf Valenta
    Medical University of Vienna, Austria
    Annu Rev Immunol 28:211-41. 2010
    ....
  10. ncbi Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination
    M Focke
    Department of Pathophysiology, Vienna General Hospital, Medical University of Vienna, Austria
    Clin Exp Allergy 34:1525-33. 2004
    ..Almost 100 million allergic patients are sensitized to the major birch pollen allergen, Bet v 1, a 17 kDa protein containing most of the IgE epitopes present in pollens of trees belonging to the Fagales order and plant-derived food...
  11. ncbi Linking allergy to autoimmune disease
    Rudolf Valenta
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, A 1090 Vienna, Austria
    Trends Immunol 30:109-16. 2009
    ..Moreover, autoantigens that activate Th1-immune responses could contribute to chronic inflammation in allergy, thus linking allergy to autoimmunity...
  12. ncbi Recombinant allergens for immunotherapy
    Rudolf Valenta
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology, Center of Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 119:826-30. 2007
    ..The obtained results hold promise that recombinant allergen-based immunotherapy will improve current immunotherapy practice and may open possibilities for new treatment strategies and possibly even for prophylactic vaccination...
  13. ncbi Component-resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area
    R Valenta
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Austria
    J Investig Allergol Clin Immunol 17:36-40. 2007
    ..Here, we describe allergen molecules from these sources that can be used for component-resolved diagnosis of allergy to facilitate the selection of patients for SIT and monitor the immunological effects of treatment...
  14. ncbi Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen
    S Vrtala
    Institute of General and Experimental Pathology, Vienna General Hospital, University of Vienna, Austria
    J Immunol 163:5489-96. 1999
    ....
  15. ncbi Vaccination with genetically engineered allergens prevents progression of allergic disease
    V Niederberger
    Department of Otorhinolaryngology, Vienna General Hospital, University of Vienna, 1090 Vienna, Austria
    Proc Natl Acad Sci U S A 101:14677-82. 2004
    ..Vaccination with genetically engineered allergen derivatives is a therapy for allergy that not only ameliorates allergic reactions but also reduces the IgE production underlying the disease...
  16. ncbi Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients
    K W Chen
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Allergy 67:609-21. 2012
    ..The aim of this study was to develop and characterize an allergy vaccine based on carrier-bound Der p 2 peptides, which should allow reducing IgE- and T-cell-mediated side-effects during specific immunotherapy (SIT)...
  17. ncbi Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination
    M Focke
    Department of Pathophysiology, Vienna General Hospital, AKH, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    FASEB J 15:2042-4. 2001
    ..We thus demonstrate that synthetic hypoallergenic peptides derived from B cell epitopes of major allergens represent safe vaccine candidates for the treatment of IgE- mediated allergies...
  18. ncbi Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation
    E Gadermaier
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18 20, Vienna, Austria
    Allergy 66:1174-82. 2011
    ..Subcutaneous injection immunotherapy (SCIT) is considered as antigen-specific and disease-modifying treatment with long-lasting effect...
  19. ncbi Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination
    T Ball
    Department of Pathophysiology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Austria
    Allergy 64:569-80. 2009
    ..Our objective was the construction, purification and immunologic characterization of a genetically modified derivative of the major timothy grass pollen allergen, Phl p 1 for immunotherapy of grass pollen allergy...
  20. ncbi Mucosal tolerance induction with hypoallergenic molecules in a murine model of allergic asthma
    U Wiedermann
    Department of Pathophysiology, University of Vienna, Austria
    Int Arch Allergy Immunol 124:391-4. 2001
    ..We conclude from our studies that mucosal tolerance induction with hypoallergenic molecules could provide a safe and convenient treatment strategy against type I allergies...
  21. ncbi Recombinant allergen molecules: tools to study effector cell activation
    R Valenta
    Department of Pathophysiology, Vienna General Hospital, University of Vienna, Austria
    Immunol Rev 179:119-27. 2001
    ..Such allergen derivatives may be used for allergen-specific immunotherapy with reduced risk of inducing anaphylactic side effects...
  22. ncbi Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy
    T E Twaroch
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 42:966-75. 2012
    ..The mould Alternaria alternata is a major elicitor of allergic asthma. Diagnosis and specific immunotherapy (SIT) of Alternaria allergy are often limited by the insufficient quality of natural mould extracts...
  23. ncbi Detection of an allergen in dog dander that cross-reacts with the major cat allergen, Fel d 1
    R Reininger
    Clinical Institute for Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 37:116-24. 2007
    ..A considerable proportion of animal-allergic patients are sensitized to both cat and dog allergens but knowledge about cross-reactive allergens in cat and dog dander is limited...
  24. ncbi Molecular characterization of wheat allergens specifically recognized by patients suffering from wheat-induced respiratory allergy
    S Pahr
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, Vienna, Austria
    Clin Exp Allergy 42:597-609. 2012
    ..Wheat (Triticum aestivum) is an important allergen source responsible for various clinical manifestations of allergy (i.e. food allergy, pollen allergy, respiratory allergy to flour-Baker's asthma)...
  25. ncbi Variability of IgE reactivity profiles among European mite allergic patients
    M Weghofer
    Division of Immunopathology, Department of Pathophysiology, Centre for Physiology and Pathophysiology, Medical University of Vienna, Austria
    Eur J Clin Invest 38:959-65. 2008
    ..Our aim was to determine the frequencies of IgE reactivity to purified HDM allergen molecules in mite allergic patients from different parts of Europe in order to establish an allergen panel for diagnosis of HDM allergy...
  26. ncbi Comparison of purified Dermatophagoides pteronyssinus allergens and extract by two-dimensional immunoblotting and quantitative immunoglobulin E inhibitions
    M Weghofer
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 35:1384-91. 2005
    ..CONCLUSION: The studied recombinant and natural mite allergens contain a large portion of Der p-specific IgE and may be used for diagnostic tests and therapy of Der p allergy...
  27. ncbi Recombinant allergens promote expression of aminopeptidase-n (CD13) on basophils in allergic patients
    K Sonneck
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Int J Immunopathol Pharmacol 21:11-21. 2008
    ..In aggregate, our data show that recombinant allergens promote expression of CD13 on basophils in sensitized individuals. The functional significance and diagnostic implications of this observation remain to be determined...
  28. ncbi Characterization of recombinant cat albumin
    R Reininger
    Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Vienna, Austria
    Clin Exp Allergy 33:1695-702. 2003
    ..CONCLUSIONS: Recombinant cat albumin may be used as a paradigmatic tool to analyse mechanisms of allergen-triggered exacerbation of AD, for diagnostic and, perhaps for therapeutic purposes...
  29. ncbi Patients suffering from non-IgE-mediated cow's milk protein intolerance cannot be diagnosed based on IgG subclass or IgA responses to milk allergens
    H Hochwallner
    Department of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
    Allergy 66:1201-7. 2011
    ....
  30. ncbi Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies
    N Mothes
    Department of Pathophysiology, Vienna General Hospital, University of Vienna, Vienna, Austria
    Clin Exp Allergy 33:1198-208. 2003
    ..These blocking antibodies may have protective effects by inhibiting immediate-type reactions and systemic increases of IgE responses caused by seasonal allergen exposure...
  31. ncbi The majority of allergen-specific IgE in the blood of allergic patients does not originate from blood-derived B cells or plasma cells
    J Eckl-Dorna
    Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 42:1347-55. 2012
    ..The production of allergen-specific IgE antibodies is a hallmark of IgE-mediated allergy but the contribution of blood cells to allergen-specific IgE production in allergic patients has not been studied in detail...
  32. ncbi Molecular characterization of Der p 10: a diagnostic marker for broad sensitization in house dust mite allergy
    Y Resch
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaAllergy Centre Vienna West, Vienna, Austria
    Clin Exp Allergy 41:1468-77. 2011
    ..Tropomyosins represent clinically relevant seafood allergens but the role of mite tropomyosin, Der p 10, in house dust mite (HDM) allergy has not been studied in detail...
  33. ncbi Association of allergic patients' phenotypes with IgE reactivity to recombinant pollen marker allergens
    A Twardosz-Kropfmüller
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Allergy 65:296-303. 2010
    ..The aim of this study was to investigate whether IgE reactivity to recombinant pollen allergens with broad and narrow cross-reactivity is associated with clinical phenotypes of allergic sensitization...
  34. ncbi Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide
    E Gadermaier
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
    Int Arch Allergy Immunol 151:17-27. 2010
    ..In the present study, we analyze the epitope specificities of antibody responses induced by SCIT with allergen extracts from pollen of trees belonging to the order Fagales (birch, alder, hazel) adsorbed onto aluminum hydroxide...
  35. ncbi Characterization of Der p 21, a new important allergen derived from the gut of house dust mites
    M Weghofer
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Allergy 63:758-67. 2008
    ..The house dust mite (HDM) Dermatophagoides pteronyssinus is a major allergen source eliciting allergic asthma. The aim of the study was to identify new important HDM allergens associated with allergic asthma...
  36. ncbi Immunotherapy of allergic disease
    R Valenta
    Division of Immunopathology, Department of Pathophysiology, University of Vienna, Medical School, Austria
    Adv Immunol 82:105-53. 2004
  37. ncbi Different allergenic activity of grass pollen allergens revealed by skin testing
    K Westritschnig
    Medical University of Vienna, Austria
    Eur J Clin Invest 38:260-7. 2008
    ....
  38. ncbi Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity
    M Focke
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology, Center for Pathophysiology, Immunology and Infectiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 40:385-97. 2010
    ..Should these peptide vaccines prove efficacious and safe in clinical trials, it may become possible to develop convenient, safe and broadly applicable forms of SIT as true alternatives to symptomatic, drug-based allergy treatment...
  39. ncbi A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor-bound IgE
    S Laffer
    Department of Pathophysiology, AKH, University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 108:409-16. 2001
    ..CONCLUSION: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells...
  40. ncbi IgA cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease
    S Natter
    Department of Pathophysiology, AKH, University of Vienna, Vienna, Austria
    Eur J Immunol 31:918-28. 2001
    ....
  41. ncbi Basophils are not the key antigen-presenting cells in allergic patients
    J Eckl-Dorna
    Department of Otorhinolaryngology, Medical University of Vienna, AKH, Vienna, Austria
    Allergy 67:601-8. 2012
    ..Here, we investigate whether basophils are of importance for the presentation of allergen and the induction of T cell proliferation in allergic patients...
  42. ncbi Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1
    S Vrtala
    Department of Pathophysiology, Vienna General Hospital, University of Vienna Medical School, Waeringer Guertel 18-20, A-1090 Vienna, Austria
    FASEB J 15:2045-7. 2001
    ..Thus, rBet v 1 trimer represents a novel hypoallergenic vaccine prototype for treatment of one of the most frequent allergy forms...
  43. ncbi Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens
    G Pittner
    Division of Immunopathology, Department of Pathophysiology, Vienna General Hospital, Medical University of Vienna, Austria
    Clin Exp Allergy 34:597-603. 2004
    ..g. Der p 10) may improve the diagnostic selection of patients for immunotherapy with Der p extracts. These tests may also be used for the immunological monitoring of patients undergoing immunotherapy...
  44. ncbi The allergen profile of beech and oak pollen
    C Egger
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 38:1688-96. 2008
    ..Beech and oak pollen are potential allergen sources with a world-wide distribution...
  45. ncbi Molecular composition and biological activity of commercial birch pollen allergen extracts
    M Focke
    Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 39:429-36. 2009
    ..The aim of this study was to analyse birch pollen allergen extracts produced for in vivo diagnosis of birch pollen allergy regarding their contents of individual birch pollen allergens (Bet v 1, Bet v 2 and Bet v 4)...
  46. ncbi Microarray and allergenic activity assessment of milk allergens
    H Hochwallner
    Department of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 40:1809-18. 2010
    ..5% of infants in the first years of their life. However, only limited information regarding the allergenic activity of individual cow's milk allergens is available...
  47. ncbi Analysis of the sensitization profile towards allergens in central Africa
    K Westritschnig
    Department of Pathophysiology, University of Vienna, Vienna, Austria
    Clin Exp Allergy 33:22-7. 2003
    ....
  48. ncbi The allergen profile of ash (Fraxinus excelsior) pollen: cross-reactivity with allergens from various plant species
    V Niederberger
    Department of Otorhinolaryngology, Vienna General Hospital, University of Vienna, Vienna, Austria
    Clin Exp Allergy 32:933-41. 2002
    ..The fact that ash pollen-allergic patients can be discriminated on the basis of their specific IgE reactivity profile to highly or moderately cross-reactive allergens has implications for the selection of appropriate forms of treatment...
  49. ncbi The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice
    B Winkler
    Department of Specific Prophylaxis and Tropical Medicine, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Allergy 61:173-80. 2006
    ....
  50. ncbi Interleukin-3 promotes the expression of E-NPP3/CD203C on human blood basophils in healthy subjects and in patients with birch pollen allergy
    A W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Int J Immunopathol Pharmacol 20:267-78. 2007
    ..Compared to FcepsilonRI-mediated cell activation, IL-3-induced upregulation of CD203c is a late(r) event and is not accompanied by upregulation of CD63...
  51. ncbi A high-affinity monoclonal anti-IgE antibody for depletion of IgE and IgE-bearing cells
    S Laffer
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Allergy 63:695-702. 2008
    ..In this study, we assessed the binding kinetics and affinity of monoclonal antibody 12 (mAb12) for IgE and investigated whether mAb12 can be used for depletion of IgE and isolation of IgE-bearing cells from peripheral blood...
  52. ncbi Molecular and immunological characterization of arginine kinase from the Indianmeal moth, Plodia interpunctella, a novel cross-reactive invertebrate pan-allergen
    M Binder
    Division of Specific Prophylaxis and Tropical Medicine and Immunopathology, Department of Pathophysiology, University of Vienna, Vienna, Austria
    J Immunol 167:5470-7. 2001
    ..Recombinant arginine kinase may be used to identify a group of polysensitized indoor allergic patients and for immunotherapy of these individuals...
  53. ncbi Escherichia coli expression and purification of recombinant dog albumin, a cross-reactive animal allergen
    B Pandjaitan
    Institute of Medical and Chemical Laboratory Diagnostics, AKH, University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 105:279-85. 2000
    ..Diagnosis and therapy of animal allergy would benefit from the availability of defined recombinant allergens. They may be preferred to animal-derived proteins, particularly for in vivo application in patients...
  54. ncbi Heterogeneity of commercial timothy grass pollen extracts
    M Focke
    Christian Doppler Laboratory for Allergy Research, Department of Pathophysiology, Center for Physiology and Pathophysiology, Vienna General Hospital, Medical University of Vienna, Austria
    Clin Exp Allergy 38:1400-8. 2008
    ..The diagnosis and specific immunotherapy of allergy is currently performed with allergen extracts prepared from natural allergen sources...
  55. ncbi Recombinant monoclonal human immunoglobulin E to investigate the allergenic activity of major grass pollen allergen Phl p 5
    C Madritsch
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 41:270-80. 2011
    ..Allergen recognition by IgE antibodies is a key event in allergic inflammation...
  56. ncbi Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules
    I Pree
    Department of Otorhinolaryngology, Medical University of Vienna, Wahringer Gurtel 18 20, Vienna, Austria
    Clin Exp Allergy 40:1346-52. 2010
    ..Vaccination with hypoallergenic recombinant Bet v 1 derivatives (Bet v 1 fragments and Bet v 1 trimer) is associated with the induction of IgG antibodies specific to natural Bet v 1...
  57. ncbi Micro-arrayed wheat seed and grass pollen allergens for component-resolved diagnosis
    C Constantin
    Division of Immunopathology, Department of Pathophysiology, Center of Physiology and Pathophysiology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Allergy 64:1030-7. 2009
    ..The aim of the study was to develop an allergen micro-array for differential diagnosis of baker's asthma, wheat-induced food allergy and grass pollen allergy...
  58. ncbi Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7
    Kerstin Westritschnig
    Department of Pathophysiology, Vienna General Hospital, AKH, Medical University of Vienna, Vienna, Austria
    J Immunol 172:5684-92. 2004
    ....
  59. ncbi Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy
    Ines Swoboda
    Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Vienna, Austria
    J Immunol 168:4576-84. 2002
    ..01. The latter results suggest that it will be possible to develop strategies for immunotherapy for fish allergy that are based on calcium-free hypoallergenic rCyp c 1.01 derivatives...
  60. ncbi IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune disease
    P Skyllouriotis
    General and Experimental Pathology, Vienna General Hospital, University of Vienna, Medical School, Vienna, Austria
    Clin Exp Immunol 115:236-47. 1999
    ....
  61. ncbi Cigarette smoke facilitates allergen penetration across respiratory epithelium
    K Gangl
    Department of Otorhinolaryngology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
    Allergy 64:398-405. 2009
    ..We sought to investigate in an in vitro system whether active smoking reduces the integrity and barrier function of the respiratory epithelium and thus facilitates allergen penetration...
  62. ncbi Sensitization to human milk
    U Schulmeister
    Institute of Clinical and Medical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 38:60-8. 2008
    ..Allergy to milk is one of the earliest manifestations of IgE-mediated allergies and affects about 2.5% of newborn children. Several reports indicate that milk-allergic patients may be sensitized also to human milk proteins...
  63. ncbi Microarrayed recombinant allergens for diagnosis of allergy
    C Harwanegg
    VBC Genomics Bioscience Research GmbH, Vienna, Austria
    Clin Exp Allergy 33:7-13. 2003
    ..The wealth of diagnostic information gained through microarray-based allergy testing will likely improve diagnosis, prevention and treatment of allergy...
  64. ncbi Molecular characterization of a human immunoglobulin G4 antibody specific for the major birch pollen allergen, Bet v 1
    S Flicker
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Waehringer Guertel, Vienna, Austria
    Clin Exp Allergy 38:365-73. 2008
    ..Objective Our aim was the molecular characterization of a human IgG4 antibody (BAB5) specific for the major birch pollen allergen Bet v 1 that was derived from an immunotherapy-treated patient...
  65. ncbi Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein
    Nadine Mothes-Luksch
    Division of Immunopathology, Department of Pathophysiology, Center of Physiology, Pathophysiology and Immunology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
    J Immunol 181:4864-73. 2008
    ..The mosaic strategy is a general strategy for the reduction of allergenic activity of protein allergens and can be used to convert harmful allergens into safe vaccines...
  66. ncbi Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy
    Birgit Linhart
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology, Center of Physiology and Pathophysiology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Immunol 178:3924-31. 2007
    ..Our results indicate that T cell suppression alone without active immune regulation or a shifting of the Th2/Th1 balance is not sufficient for the treatment of established IgE responses in an allergy...
  67. ncbi A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination
    Birgit Linhart
    Cenetr of Physiology and Pathophysiology, Department of Pathophysiology, Medical University of Vienna, Austria
    J Allergy Clin Immunol 115:1010-6. 2005
    ..CONCLUSION: We demonstrate for grass pollen allergy that recombinant hybrid molecules covering the spectrum of the disease-eliciting epitopes of complex allergen sources can be engineered...
  68. ncbi Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity
    Susanne Vrtala
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    J Immunol 179:1730-9. 2007
    ..They show that it has to be demonstrated that the hypoallergenic derivative induces a robust IgG response in a formulation that can be used in allergic patients...
  69. ncbi Evaluation of the allergenic potential of Ginkgo biloba extracts
    R Mossabeb
    Department of Pathophysiology, University of Vienna, Austria
    Wien Klin Wochenschr 113:580-7. 2001
    ..In conclusion, no evidence for the presence of type I allergens in Ginkgo extracts was found. We recommend serological and/or skin testing to exclude sensitisation to components of Ginkgo biloba extracts...
  70. ncbi Identification of oilseed rape (Brassica napus) pollen profilin as a cross-reactive allergen
    Margarete Focke
    FAZ Floridsdorf Allergy Centre, University of Vienna, Vienna, Austria
    Int Arch Allergy Immunol 132:116-23. 2003
    ..Major allergens of oilseed rape (OSR) pollen with molecular weights of 6/8, 14 and between 27 and 69 kD have been described. The aim of the present study was to further characterize the 14-kD allergen...
  71. ncbi Immunoglobulin E antibody reactivity to bacterial antigens in atopic dermatitis patients
    K Reginald
    Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 41:357-69. 2011
    ..AD patients are often sensitized against a broad variety of allergens and more than 90% of them suffer from skin superinfections with Staphylococcus aureus...
  72. ncbi A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin
    Kerstin Westritschnig
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    J Immunol 179:7624-34. 2007
    ..The strategy of tail-to-head reassembly of hypoallergenic allergen fragments within one molecule represents a generally applicable strategy for the generation of allergy vaccines...
  73. ncbi A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1
    Johanna Edlmayr
    Department of Pathophysiology, Division of Immunopathology, Christian Doppler Laboratory for Allergy Research, University of Vienna, Vienna, Austria
    J Immunol 182:6298-306. 2009
    ..The principle of fusing nonallergenic allergen-derived peptides onto viral carrier proteins may be used for the engineering of safe allergy vaccines which also protect against viral infections...
  74. ncbi Molecular characterization of polygalacturonases as grass pollen-specific marker allergens: expulsion from pollen via submicronic respirable particles
    Ines Swoboda
    Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
    J Immunol 172:6490-500. 2004
    ..Our finding that rabbit anti-rPhl p 13 Abs blocked patients' IgE binding to the allergen suggests that rPhl p 13 may be used for immunotherapy of sensitized patients...
  75. ncbi Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice
    Karin Hufnagl
    Department of Specific Prophylaxis and Tropical Medicine, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 116:370-6. 2005
    ..Thus, mucosal coapplication of selected peptides/hybrid peptides could be the basis of a mucosal polyvalent vaccine to prevent multiple sensitivities in atopic patients...
  76. ncbi Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity
    Jürgen Reisinger
    Department of Otorhinolaryngology, Center for Physiology and Pathophysiology, Vienna General Hospital, Vienna, Austria
    J Allergy Clin Immunol 116:347-54. 2005
    ..We have performed a double-blind, placebo-controlled injection immunotherapy study with genetically modified derivatives of the major birch pollen allergen, Bet v 1 (Bet v 1-trimer, Bet v 1-fragments)...
  77. ncbi Persistent molecular microchimerism induces long-term tolerance towards a clinically relevant respiratory allergen
    U Baranyi
    Division of Transplantation, Department of Surgery, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 42:1282-92. 2012
    ..e. macrochimerism) and completely abrogated Phl p 5-specific immunity despite repeated immunizations with Phl p 5...
  78. ncbi Recombinant allergen-based concepts for diagnosis and therapy of type I allergy
    R Valenta
    Department of Pathophysiology, Vienna General Hospital-AKH, University of Vienna Medical School, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    Allergy 57:66-7. 2002
  79. ncbi Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients
    R Valenta
    Institute of General and Experimental Pathology, Vienna General Hospital, University of Vienna Medical School, Austria
    J Invest Dermatol 111:1178-83. 1998
    ..If so, the respective recombinant molecule may serve as a paradigmatic tool for the diagnosis and treatment of patients with "intrinsic" atopy...
  80. ncbi A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6
    Birgit Linhart
    Division of Immunopathology, Department of Pathophysiology, Center of Physiology, Pathophysiology and Immunology, Medical University of Vienna, Vienna, Austria
    Biol Chem 389:925-33. 2008
    ..These antibodies could inhibit patients' IgE binding to the wild-type allergens. Thus, the described strategy allows the development of safer and more efficacious vaccines for the treatment of grass pollen allergy...
  81. ncbi Characterization of folded recombinant Der p 5, a potential diagnostic marker allergen for house dust mite allergy
    Margit Weghofer
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Int Arch Allergy Immunol 147:101-9. 2008
    ..The aim of this study was to produce, by recombinant DNA technology, a folded Der p 5 allergen for diagnostic, therapeutic and preventive purposes...
  82. ncbi Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man
    Ines Pree
    Department of Otolaryngology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
    J Immunol 179:5309-16. 2007
    ..These data may be important for the development of therapeutic as well as prophylactic vaccines based on recombinant allergens...
  83. ncbi Trimolecular complex formation of IgE, Fc epsilon RI, and a recombinant nonanaphylactic single-chain antibody fragment with high affinity for IgE
    Christian Lupinek
    Department of Pathophysiology, Division of Immunopathology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    J Immunol 182:4817-29. 2009
    ..In vivo skin testing confirmed the lack of allergenic activity of the ScFv. The recombinant ScFv may represent a universal tool for the IgE-targeted treatment of allergies...
  84. ncbi Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells
    Ulrike Baranyi
    Division of Transplantation, Department of Surgery, Center of Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    J Immunol 180:8168-75. 2008
    ..B cell, T cell, and effector cell responses to an unrelated control allergen (Bet v 1) were unperturbed, demonstrating specificity of this tolerance protocol. We thus describe a novel cell-based strategy for the prevention of allergy...
  85. ncbi Transition from a botanical to a molecular classification in tree pollen allergy: implications for diagnosis and therapy
    Nadine Mothes
    Center for Physiology and Pathophysiology, Department of Pathophysiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
    Int Arch Allergy Immunol 135:357-73. 2004
    ..Information obtained by diagnostic testing with marker allergens will be important for the appropriate selection of patients for allergen-specific forms of therapy...
  86. ncbi Genetically modified allergens
    Verena Niederberger
    Department of Otorhinolaryngology, Vienna General Hospital, Medical University of Vienna, Ebene 8J, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Immunol Allergy Clin North Am 24:727-38. 2004
    ..This article summarizes data on genetically modified recombinant allergen derivatives with reduced allergenic activity, which may be used to improve the safety and efficacy of specific immunotherapy...
  87. ncbi Identification of a villin-related tobacco protein as a novel cross-reactive plant allergen
    Irene Mittermann
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    FEBS Lett 579:3807-13. 2005
    ..They may be used for the diagnosis and treatment of patients suffering from multivalent plant allergies...
  88. ncbi Tree pollen allergens
    Nadine Mothes
    University of Vienna, Vienna Medical School, Vienna, Austria
    Clin Allergy Immunol 18:165-84. 2004
  89. ncbi Molecular design of allergy vaccines
    Birgit Linhart
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    Curr Opin Immunol 17:646-55. 2005
    ....
  90. ncbi Molecular approaches for new vaccines against allergy
    Verena Niederberger
    Department of Otolaryngology, Vienna General Hospital, AKH, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Expert Rev Vaccines 5:103-10. 2006
    ..Vaccination with the Bet v 1-derivatives improved symptoms of birch pollen allergy, induced a healthy allergen-specific immunoglobulin G response and led to a significant reduction of seasonally induced boosts of immunoglobulin E...
  91. ncbi Allergy testing: the role of recombinant allergens
    Nadine Mothes
    Zentrum für Physiologie und Pathophysiologie, Institut fur Pathophysiologie, Abteilung Immunpathologie, Medizinische Universität Wien, Vienna, Austria
    Clin Chem Lab Med 44:125-32. 2006
    ..Besides their diagnostic application, recombinant allergens and hypoallergenic derivatives thereof have also been used as vaccines in clinical trials, and recent results have shown their usefulness for the treatment of type I allergy...
  92. ncbi Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity
    Sabine Flicker
    Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Austria
    J Allergy Clin Immunol 117:1336-43. 2006
    ..It might also form a basis for the development of low allergenic vaccines...
  93. ncbi Identification of cross-reactive and genuine Parietaria judaica pollen allergens
    Sabine Stumvoll
    Department of Pathophysiology, AKH, University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 111:974-9. 2003
    ....
  94. ncbi Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody
    Sabine Flicker
    Department of Pathophysiology, Vienna General Hospital, University of Vienna, Vienna, Austria
    Eur J Immunol 32:2156-62. 2002
    ..The recombinant human Phl p 2-specific IgG(1) may be used for environmental allergen detection, for standardization of diagnostic as well as therapeutic grass pollen allergen preparations and for passive therapy of grass pollen allergy...
  95. ncbi A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy
    Ines Swoboda
    Institute of Medical and Chemical Laboratory Diagnostics, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Austria
    J Immunol 178:6290-6. 2007
    ..Using the hypoallergenic carp parvalbumin mutant Mut-CD/EF, it may be possible to treat fish allergy by immunotherapy...
  96. ncbi Recombinant allergens promote expression of CD203c on basophils in sensitized individuals
    Alexander W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 110:102-9. 2002
    ....
  97. ncbi Purification, structural and immunological characterization of a timothy grass (Phleum pratense) pollen allergen, Phl p 4, with cross-reactive potential
    Sabine Stumvoll
    Department of Pathophysiology, University of Vienna, Austria
    Biol Chem 383:1383-96. 2002
    ..Rabbit antibodies raised against Phl p 4 also inhibited the binding of allergic patients IgE to Phl p 4. Phl p 4 may thus be used for diagnosis and treatment of sensitized allergic patients...
  98. ncbi Synthetic and genetically engineered allergen derivatives for specific immunotherapy of type I allergy
    Rudolf Valenta
    Vienna General Hospital (AKH, University of Vienna Medical School, Vienna, Austria
    Clin Allergy Immunol 16:495-517. 2002
  99. ncbi Vaccine engineering improved by hybrid technology
    Birgit Linhart
    Department of Pathophysiology, Medical University of Vienna, Vienna, Austria
    Int Arch Allergy Immunol 134:324-31. 2004
    ..We exemplify the use of hybrid technology for the generation of new allergy vaccines and discuss its potential applicability for the development of vaccines for infectious diseases, cancer and autoimmunity...
  100. ncbi Biology of tree pollen allergens
    Nadine Mothes
    Division of Immunopathology, Department of Pathophysiology, Vienna General Hospital, AKH, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    Curr Allergy Asthma Rep 4:384-90. 2004
    ..Moreover, we describe novel recombinant allergen-based forms of specific immunotherapy...
  101. ncbi Autoimmunity and atopic dermatitis
    Irene Mittermann
    Department of Pathophysiology, Division of Immunopathology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
    Curr Opin Allergy Clin Immunol 4:367-71. 2004
    ..The levels of IgE autoantibodies correspond with disease severity. Several mechanisms of IgE autoimmunity may contribute to the pathogenesis of atopic dermatitis...